RU95110774A - Олигонуклеотиды, терапевтические композиции, применение композиций - Google Patents

Олигонуклеотиды, терапевтические композиции, применение композиций

Info

Publication number
RU95110774A
RU95110774A RU95110774/04A RU95110774A RU95110774A RU 95110774 A RU95110774 A RU 95110774A RU 95110774/04 A RU95110774/04 A RU 95110774/04A RU 95110774 A RU95110774 A RU 95110774A RU 95110774 A RU95110774 A RU 95110774A
Authority
RU
Russia
Prior art keywords
compositions
therapeutical
oligonulceotides
abnormal
derivatives
Prior art date
Application number
RU95110774/04A
Other languages
English (en)
Other versions
RU2112766C1 (ru
Inventor
Колот Судир
Fr]
Пиротзки Эдуардо
Original Assignee
Сосьете де Консей де Решерш э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) (FR)
Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сосьете де Консей де Решерш э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) (FR), Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) filed Critical Сосьете де Консей де Решерш э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) (FR)
Publication of RU95110774A publication Critical patent/RU95110774A/ru
Application granted granted Critical
Publication of RU2112766C1 publication Critical patent/RU2112766C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01029—Geranylgeranyl diphosphate synthase (2.5.1.29)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к олигонуклеотидам и их производным для подавления экспрессии изопренил-протеин-трансфераз, терапевтическим композициям, содержащим такие соединения, и к использованию таких композиций олигонуклеотидов для лечения или терапии заболеваний человека или животных, вызванных ненормальной и/или нерегулируемой пролиферацией.

Claims (1)

  1. Изобретение относится к олигонуклеотидам и их производным для подавления экспрессии изопренил-протеин-трансфераз, терапевтическим композициям, содержащим такие соединения, и к использованию таких композиций олигонуклеотидов для лечения или терапии заболеваний человека или животных, вызванных ненормальной и/или нерегулируемой пролиферацией.
RU95110774/04A 1994-06-29 1995-06-28 Олигонуклеотиды, фармацевтическая композиция RU2112766C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9413035A GB9413035D0 (en) 1994-06-29 1994-06-29 Antisense oligonucleeotides
GB9413035.8 1994-06-29

Publications (2)

Publication Number Publication Date
RU95110774A true RU95110774A (ru) 1997-04-20
RU2112766C1 RU2112766C1 (ru) 1998-06-10

Family

ID=10757497

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95110774/04A RU2112766C1 (ru) 1994-06-29 1995-06-28 Олигонуклеотиды, фармацевтическая композиция

Country Status (25)

Country Link
US (1) US5856461A (ru)
EP (1) EP0692535A1 (ru)
JP (1) JPH0851985A (ru)
KR (1) KR960000914A (ru)
CN (1) CN1124142A (ru)
AU (1) AU689887B2 (ru)
BR (1) BR9503015A (ru)
CA (1) CA2152233A1 (ru)
CZ (1) CZ291496B6 (ru)
DZ (1) DZ1903A1 (ru)
FI (1) FI953170A (ru)
FR (2) FR2721930B1 (ru)
GB (2) GB9413035D0 (ru)
HU (1) HU219823B (ru)
IE (1) IE950477A1 (ru)
MA (1) MA23595A1 (ru)
NO (1) NO952601L (ru)
NZ (1) NZ272398A (ru)
OA (1) OA10221A (ru)
PL (1) PL309384A1 (ru)
RU (1) RU2112766C1 (ru)
SE (1) SE9502259L (ru)
SK (1) SK83895A3 (ru)
TN (1) TNSN95068A1 (ru)
ZA (1) ZA955288B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002817A1 (en) * 1995-07-13 1997-01-30 University Of Cincinnati Compounds useful in the treatment of neurofibromatosis
CN1301731A (zh) * 1999-12-24 2001-07-04 上海博德基因开发有限公司 一种新的多肽——多异戊二烯基合成酶蛋白9和编码这种多肽的多核苷酸
AU2002230651A1 (en) * 2000-12-07 2002-06-18 Bristol-Myers Squibb Company Human g-protein coupled receptor expressed highly in kidney
US20030212017A1 (en) * 2002-05-10 2003-11-13 Isis Pharmaceuticals Inc. Antisense modulation of farnesyl transferase beta subunit expression
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
EP1667522B1 (en) 2003-09-09 2018-01-17 Geron Corporation Modified oligonucleotides for telomerase inhibition
US8785409B2 (en) * 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5185248A (en) * 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
KR100242671B1 (ko) * 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
NZ244820A (en) * 1991-10-25 1994-01-26 Isis Pharmaceuticals Inc Oligonucleotide inhibitor of epstein-barr virus.
US5348853A (en) * 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA

Also Published As

Publication number Publication date
GB9513246D0 (en) 1995-09-06
HU9501913D0 (en) 1995-08-28
RU2112766C1 (ru) 1998-06-10
CN1124142A (zh) 1996-06-12
FR2721930B1 (fr) 1997-01-03
DZ1903A1 (fr) 2002-02-17
GB2290791A (en) 1996-01-10
EP0692535A1 (fr) 1996-01-17
FR2721827A1 (fr) 1996-01-05
FI953170A (fi) 1995-12-30
US5856461A (en) 1999-01-05
CA2152233A1 (en) 1995-12-30
NO952601L (no) 1996-01-02
SK83895A3 (en) 1996-05-08
SE9502259L (sv) 1995-12-30
FI953170A0 (fi) 1995-06-27
HU219823B (hu) 2001-08-28
AU689887B2 (en) 1998-04-09
ZA955288B (en) 1996-01-31
CZ168895A3 (en) 1996-05-15
HUT72133A (en) 1996-03-28
JPH0851985A (ja) 1996-02-27
NZ272398A (en) 1996-04-26
GB2290791B (en) 1998-08-05
SE9502259D0 (sv) 1995-06-21
AU2329995A (en) 1996-01-11
CZ291496B6 (cs) 2003-03-12
TNSN95068A1 (fr) 1996-02-06
BR9503015A (pt) 1996-06-04
MA23595A1 (fr) 1995-12-31
OA10221A (fr) 1997-09-19
IE950477A1 (en) 1996-01-10
NO952601D0 (no) 1995-06-28
KR960000914A (ko) 1996-01-25
FR2721930A1 (fr) 1996-01-05
GB9413035D0 (en) 1994-08-17
PL309384A1 (en) 1996-01-08

Similar Documents

Publication Publication Date Title
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
IL122248A (en) Use of nisin in the manufacture of a medicament for the treatment of an infection and pharmaceutical compositions comprising nisin for said treatment
HK1085386A1 (en) Pharmaceuticals comprising shikonins active constituent
DE60221283D1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
MY132437A (en) New applications of lysozyme dimer
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
EP1361905B8 (en) Matrix protein compositions for guided connective tissue growth
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
ATE213637T1 (de) Bismut enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
RU93052444A (ru) Лекарственный препарат бан
BR9810095A (pt) Dispositivos para distribuição de droga e métodospara tratamento de infecções virais e microbianase de sìndromes de emaciação

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20030629